The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors

The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, r...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The European respiratory journal Ročník 49; číslo 1
Hlavní autoři:	Ellwood, Philippa, Asher, M Innes, Billo, Nils E, Bissell, Karen, Chiang, Chen-Yuan, Ellwood, Eamon M, El-Sony, Asma, García-Marcos, Luis, Mallol, Javier, Marks, Guy B, Pearce, Neil E, Strachan, David P
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.01.2017
Témata:	Adolescent Asthma - epidemiology Asthma - therapy Child Clinical Protocols Cross-Sectional Studies Eczema - ethnology Epidemiological Monitoring Female Global Health Humans International Cooperation Internet Male Rhinitis - epidemiology Risk Factors Severity of Illness Index Surveys and Questionnaires
ISSN:	1399-3003, 1399-3003
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.
AbstractList	The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden. The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.
Author	Ellwood, Philippa Mallol, Javier Strachan, David P Billo, Nils E Chiang, Chen-Yuan Marks, Guy B Bissell, Karen El-Sony, Asma García-Marcos, Luis Ellwood, Eamon M Asher, M Innes Pearce, Neil E
Author_xml	– sequence: 1 givenname: Philippa orcidid: 0000-0002-1994-4023 surname: Ellwood fullname: Ellwood, Philippa email: p.ellwood@auckland.ac.nz organization: Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand p.ellwood@auckland.ac.nz – sequence: 2 givenname: M Innes surname: Asher fullname: Asher, M Innes organization: Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand – sequence: 3 givenname: Nils E surname: Billo fullname: Billo, Nils E organization: Joensuu, Finland – sequence: 4 givenname: Karen surname: Bissell fullname: Bissell, Karen organization: School of Population Health, The University of Auckland, Auckland, New Zealand – sequence: 5 givenname: Chen-Yuan surname: Chiang fullname: Chiang, Chen-Yuan organization: Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan – sequence: 6 givenname: Eamon M surname: Ellwood fullname: Ellwood, Eamon M organization: Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand – sequence: 7 givenname: Asma surname: El-Sony fullname: El-Sony, Asma organization: Epidemiological Laboratory (Epi-Lab) for Public Health, Research and Development, Khartoum, Sudan – sequence: 8 givenname: Luis surname: García-Marcos fullname: García-Marcos, Luis organization: Paediatric Allergy and Pulmonology Units, Arrixaca University Children's Hospital, University of Murcia and IMIB Bioresearch Institute, Murcia, Spain – sequence: 9 givenname: Javier surname: Mallol fullname: Mallol, Javier organization: Paediatric Respiratory Medicine, Hospital-CRS El Pino, University of Santiago de Chile, (USACH), Santiago, Chile – sequence: 10 givenname: Guy B surname: Marks fullname: Marks, Guy B organization: Dept of Medical Statistics, Respiratory and Environmental Epidemiology, South Western Sydney Clinical School, University of New South Wales, Sydney, Australia – sequence: 11 givenname: Neil E surname: Pearce fullname: Pearce, Neil E organization: Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK – sequence: 12 givenname: David P surname: Strachan fullname: Strachan, David P organization: Population Health Research Institute, St George's, University of London, London, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28077477$$D View this record in MEDLINE/PubMed
BookMark	eNpNUM1OwzAYi9AQ-4EnQEI5clhH0qZNym2aYEyagMPuVdJ8XcvaZiTZ0K48OR0bEidblm1ZHqJea1pA6JaSCaUieqBRmkaERBNCExIHYQcXaHBUg6Pc-8f7aOjcB-kcLKJXqB8KwjnjfIC-VyXgeW2UrPHU-bKR-BX8l7EbbKWvTCtrwLLVuAFfGu1wYSx-L6UDvMDrU87t7B6qupZtDo94a2HfhTo-xg72YCt_GONGtnINDbT-t81WboMLmXtj3TW6LGTt4OaMI7R6flrNXoLl23wxmy6DvFvqg7igIs0VL2KtdEqKIlIxYTIkeQKaKE6VZHks0kSEIpcsFHGkuVYSuGZhEoUjdH-q3VrzuQPns6ZyORxng9m5jIpYUCIYSzvr3dm6Uw3obGurRtpD9ndb-AP4HnM6
CitedBy_id	crossref_primary_10_1080_02652048_2019_1572239 crossref_primary_10_1371_journal_pone_0194739 crossref_primary_10_1186_s12199_018_0709_0 crossref_primary_10_3390_ijms241310467 crossref_primary_10_1016_j_phymed_2022_154008 crossref_primary_10_1007_s43450_020_00026_4 crossref_primary_10_1016_j_prrv_2018_10_002 crossref_primary_10_1007_s00784_022_04803_4 crossref_primary_10_1016_j_jacig_2022_07_006 crossref_primary_10_1016_j_pjnns_2018_07_004 crossref_primary_10_3389_fcell_2020_00444 crossref_primary_10_1080_02770903_2017_1326133 crossref_primary_10_3389_fmicb_2018_00686 crossref_primary_10_1590_0102_311x00072220 crossref_primary_10_1093_ije_dyaa108 crossref_primary_10_1111_pai_13656 crossref_primary_10_1183_13993003_02865_2021 crossref_primary_10_1016_j_asjsur_2024_05_259 crossref_primary_10_1186_s13223_022_00720_z crossref_primary_10_1136_bmjresp_2020_000658 crossref_primary_10_3390_jcm9113688 crossref_primary_10_1007_s11882_024_01173_7 crossref_primary_10_1016_j_waojou_2020_100492 crossref_primary_10_1111_jfbc_13187 crossref_primary_10_1186_s13052_017_0400_x crossref_primary_10_1007_s00281_020_00785_1 crossref_primary_10_1007_s10528_023_10635_y crossref_primary_10_1136_bmjresp_2022_001498 crossref_primary_10_1183_13993003_00440_2022 crossref_primary_10_7759_cureus_47558 crossref_primary_10_3390_ijms23084297 crossref_primary_10_1016_j_bjorl_2024_101500 crossref_primary_10_1016_j_waojou_2023_100794 crossref_primary_10_1186_s12888_025_07245_w crossref_primary_10_3390_ijerph19127457 crossref_primary_10_2105_AJPH_2020_305708 crossref_primary_10_1002_jcla_23813 crossref_primary_10_1016_S0140_6736_21_01450_1 crossref_primary_10_1080_13880209_2019_1710218 crossref_primary_10_14341_omet10083 crossref_primary_10_3390_children8100932 crossref_primary_10_3390_nu15143191 crossref_primary_10_3389_fmicb_2017_01732 crossref_primary_10_1016_j_anpedi_2021_10_007 crossref_primary_10_1016_j_waojou_2019_100092 crossref_primary_10_1016_j_waojou_2024_100948 crossref_primary_10_3390_children10020247 crossref_primary_10_1136_bmjopen_2020_046294 crossref_primary_10_1007_s00394_024_03524_6 crossref_primary_10_1208_s12249_025_03136_1 crossref_primary_10_3389_fimmu_2020_534501 crossref_primary_10_1097_ACI_0000000000000728 crossref_primary_10_7759_cureus_33391 crossref_primary_10_1016_j_jaip_2017_12_017 crossref_primary_10_1089_ped_2024_0021 crossref_primary_10_3389_fped_2021_793452 crossref_primary_10_3390_children9050686 crossref_primary_10_3390_ijerph18189688 crossref_primary_10_1016_j_arabjc_2022_103961 crossref_primary_10_1111_bph_16334 crossref_primary_10_1111_jfbc_14036 crossref_primary_10_1183_23120541_00528_2021 crossref_primary_10_3390_healthcare11071037 crossref_primary_10_1016_j_anpede_2021_10_005 crossref_primary_10_1016_j_waojou_2021_100623 crossref_primary_10_1016_j_waojou_2023_100824 crossref_primary_10_1183_13993003_02866_2021 crossref_primary_10_1136_bmjresp_2017_000260 crossref_primary_10_1002_ppul_25226 crossref_primary_10_1038_s41533_019_0126_x crossref_primary_10_1016_j_waojou_2024_100917 crossref_primary_10_1111_odi_13315 crossref_primary_10_1016_j_pharma_2025_02_003 crossref_primary_10_1007_s10792_020_01644_6 crossref_primary_10_1007_s11882_024_01172_8 crossref_primary_10_1183_13993003_02094_2020 crossref_primary_10_1016_j_jmii_2023_04_008 crossref_primary_10_1038_s41598_022_12103_w crossref_primary_10_1016_S2213_2600_24_00383_7 crossref_primary_10_1016_j_yexcr_2018_09_008 crossref_primary_10_7717_peerj_16530 crossref_primary_10_1183_13993003_01605_2016 crossref_primary_10_3389_fped_2018_00186 crossref_primary_10_1371_journal_pone_0176875 crossref_primary_10_1016_j_jclepro_2022_132965 crossref_primary_10_1007_s11882_017_0697_y crossref_primary_10_1007_s13312_025_3355_9 crossref_primary_10_1183_23120541_00576_2020 crossref_primary_10_1111_cea_14276 crossref_primary_10_1016_j_waojou_2022_100710 crossref_primary_10_1080_02770903_2024_2375272 crossref_primary_10_1080_02770903_2025_2512596 crossref_primary_10_1111_pai_70062 crossref_primary_10_1002_hsr2_70678 crossref_primary_10_1007_s00431_018_03311_6 crossref_primary_10_1016_j_jacig_2022_01_004
ContentType	Journal Article
Copyright	Copyright ©ERS 2017.
Copyright_xml	– notice: Copyright ©ERS 2017.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1183/13993003.01605-2016
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1399-3003
ExternalDocumentID	28077477
Genre	Multicenter Study Journal Article Clinical Trial, Phase I
GroupedDBID	--- .55 .GJ 18M 1OC 2WC 31~ 3O- 53G 5GY 5RE 5VS 8-1 AADJU AAFWJ AAZMJ ABCQX ABJNI ABOCM ABSQV ACEMG ACGFO ACPRK ACXQS ADBBV ADDZX ADMOG AENEX AFFNX AFHIN AFZJQ AIZTS AJAOE ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CAG CGR COF CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P F9R GX1 H13 INIJC J5H KQ8 L7B LH4 LW6 NPM OK1 P2P PQQKQ R0Z RHF RHI TER TR2 W8F WOQ X7M ZE2 ZGI ZXP ~02 7X8 ADYFA
ID	FETCH-LOGICAL-c477t-5f189cb7f5dbd90ff3b504a20c6ed0b71ba4c5896828ca42853d7dbae7d42632
IEDL.DBID	7X8
ISICitedReferencesCount	129
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000397423500035&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1399-3003
IngestDate	Thu Sep 04 17:40:33 EDT 2025 Wed Feb 19 02:43:22 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	Copyright ©ERS 2017.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c477t-5f189cb7f5dbd90ff3b504a20c6ed0b71ba4c5896828ca42853d7dbae7d42632
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-1994-4023
OpenAccessLink	https://erj.ersjournals.com/content/erj/49/1/1601605.full.pdf
PMID	28077477
PQID	1858108449
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1858108449 pubmed_primary_28077477
PublicationCentury	2000
PublicationDate	2017-01-01
PublicationDateYYYYMMDD	2017-01-01
PublicationDate_xml	– month: 01 year: 2017 text: 2017-01-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	The European respiratory journal
PublicationTitleAlternate	Eur Respir J
PublicationYear	2017
SSID	ssj0016431
Score	2.5625877
Snippet	The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
SubjectTerms	Adolescent Asthma - epidemiology Asthma - therapy Child Clinical Protocols Cross-Sectional Studies Eczema - ethnology Epidemiological Monitoring Female Global Health Humans International Cooperation Internet Male Rhinitis - epidemiology Risk Factors Severity of Illness Index Surveys and Questionnaires
Title	The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors
URI	https://www.ncbi.nlm.nih.gov/pubmed/28077477 https://www.proquest.com/docview/1858108449
Volume	49
WOSCitedRecordID	wos000397423500035&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV27TsMwFLWAIsTC-1FeukiMDU0aJ45ZUIWoYGjVoUO3yk-VoWlp2n4AX8514tIJCYklgxVHkX3s-9Q5hDwom9HI4g6g5yYCKlMaSCtYQK3heJooj1NZik2wXi8bDnnfJ9wK31a5vhPLi1pPlcuRN9GuZFGYUcqfZ5-BU41y1VUvobFNajG6Mg7VbLipIqC1rQIu7ur7YexZhxDFTTfmhh4dw1qCWInS333M0tZ0Dv_7l0fkwHuZ0K5gcUy2TH5C9rq-jn5KvhAdUNH9Q7tYjCcCelU_OMx9dtCAyDVUAtMFoGsL_TFaPHiHikMEiuV8ZZxmEcLmCWZzxxvurokGoLE1ThOvAZOf5prya66PHbzCzxkZdF4HL2-BV2MIFGVsESQ2yriSzCZaah5aG8skpKIVqtToULJICqqSjKcYwymBUU0Sa6alMEyXpPDnZCef5uaSQMw4b6ksSVqCUYUxOLp4-B46llGklWZ1cr9e3BGC3VUwRG6my2K0Wd46uah2aDSrWDlGjtYHYyN29YfZ12S_5cxzmUq5ITWLR93ckl21WnwU87sSRfjs9bvf6PzSXQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Global+Asthma+Network+rationale+and+methods+for+Phase+I+global+surveillance%3A+prevalence%2C+severity%2C+management+and+risk+factors&rft.jtitle=The+European+respiratory+journal&rft.au=Ellwood%2C+Philippa&rft.au=Asher%2C+M+Innes&rft.au=Billo%2C+Nils+E&rft.au=Bissell%2C+Karen&rft.date=2017-01-01&rft.issn=1399-3003&rft.eissn=1399-3003&rft.volume=49&rft.issue=1&rft_id=info:doi/10.1183%2F13993003.01605-2016&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1399-3003&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1399-3003&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1399-3003&client=summon